Arcus biosciences presents promising initial data from phase 1 portion of arc-8 study for ab680 in metastatic pancreatic cancer

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented preliminary data from the dose-escalation portion of its arc-8 phase 1/1b study, evaluating the safety and tolerability of ab680, the first small-molecule cd73 inhibitor to enter the clinic, in metastatic pancreatic cancer at the asco 2021 virtual gastrointestinal cancers symposium (asco gi). the ongoing, open-labe
RCUS Ratings Summary
RCUS Quant Ranking